Short Interest in TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Decreases By 78.5%

TriSalus Life Sciences, Inc. (NASDAQ:TLSI - Get Free Report) was the recipient of a large drop in short interest during the month of April. As of April 15th, there was short interest totalling 26,400 shares, a drop of 78.5% from the March 31st total of 123,000 shares. Approximately 0.2% of the company's shares are sold short. Based on an average daily volume of 49,800 shares, the days-to-cover ratio is currently 0.5 days.

TriSalus Life Sciences Stock Down 10.3 %

TLSI traded down $0.59 on Wednesday, reaching $5.13. The company's stock had a trading volume of 36,030 shares, compared to its average volume of 41,946. The company has a market capitalization of $156.43 million, a price-to-earnings ratio of -2.06 and a beta of 0.49. TriSalus Life Sciences has a fifty-two week low of $3.50 and a fifty-two week high of $10.24. The stock has a 50 day moving average of $5.51 and a two-hundred day moving average of $4.92.

TriSalus Life Sciences (NASDAQ:TLSI - Get Free Report) last announced its earnings results on Thursday, March 27th. The company reported ($0.35) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.35). The firm had revenue of $8.26 million during the quarter, compared to analyst estimates of $8.12 million. As a group, analysts anticipate that TriSalus Life Sciences will post -1.55 earnings per share for the current fiscal year.

Analyst Ratings Changes

TLSI has been the subject of a number of research analyst reports. Canaccord Genuity Group restated a "buy" rating and set a $11.00 target price on shares of TriSalus Life Sciences in a report on Friday, March 28th. Lake Street Capital began coverage on shares of TriSalus Life Sciences in a report on Thursday, February 13th. They issued a "buy" rating and a $10.00 price objective for the company. Finally, Roth Mkm reiterated a "buy" rating and set a $11.00 target price on shares of TriSalus Life Sciences in a report on Friday, January 24th. Eight equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average target price of $11.56.

Insider Activity at TriSalus Life Sciences

In other news, CFO James Emmett Young purchased 6,000 shares of the firm's stock in a transaction on Wednesday, February 5th. The shares were bought at an average cost of $5.65 per share, for a total transaction of $33,900.00. Following the completion of the purchase, the chief financial officer now directly owns 30,000 shares of the company's stock, valued at approximately $169,500. This trade represents a 25.00 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 32.80% of the stock is owned by insiders.

Hedge Funds Weigh In On TriSalus Life Sciences

Hedge funds and other institutional investors have recently bought and sold shares of the company. Geode Capital Management LLC boosted its stake in shares of TriSalus Life Sciences by 45.4% in the third quarter. Geode Capital Management LLC now owns 200,427 shares of the company's stock valued at $924,000 after buying an additional 62,542 shares in the last quarter. Virtu Financial LLC purchased a new stake in TriSalus Life Sciences during the third quarter worth about $92,000. Renaissance Technologies LLC acquired a new position in TriSalus Life Sciences during the fourth quarter worth about $67,000. Northern Trust Corp increased its holdings in TriSalus Life Sciences by 22.7% in the fourth quarter. Northern Trust Corp now owns 32,112 shares of the company's stock valued at $161,000 after buying an additional 5,936 shares in the last quarter. Finally, Bank of America Corp DE boosted its position in shares of TriSalus Life Sciences by 120,471.6% in the 4th quarter. Bank of America Corp DE now owns 178,446 shares of the company's stock worth $894,000 after buying an additional 178,298 shares in the last quarter. 2.58% of the stock is currently owned by hedge funds and other institutional investors.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.